ACVR1 Antilichaam

ACVR1 Antibody: Activins are dimeric growth and differentiation factors which belong to the transforming growth factor-beta (TGF-beta) superfamily of structurally related signaling proteins. Activins signal through a heteromeric complex of receptor serine kinases which include at least two type I and two type II receptors. Unlike ACVR1B and ACVR1C, ACVR1, also known as activin receptor-like kinase 2 (ALK2), can not transduce activin-mediated signaling, but will transduce BMP and Mullerian inhibiting substance (MIS) group signaling. It is thought that ACVR1 also inhibits activin signaling by blocking the binding of activin to its type II receptor. Recent studies indicate that genetic variation in ACVR1 is associated with polycystic ovary syndrome, suggesting that ACVR1 signaling contributes to disturbed folliculogenesis in these patients.

90

Q04771

NP_001096

Human, Mouse

Unconjugated

Primary Antibodies

Signal Transduction

ACVR1 Antibody is affinity chromatography purified via peptide column.

Cat. No. 1203 - A549 Cell Lysate

1 mg/mL

Predicted species reactivity based on immunogen sequence: Bovine: (100%), Rat: (93%)

ACVR1 Antibody is supplied in PBS containing 0.02% sodium azide.

None

Blue Ice

ACVR1 antibody can be stored at 4˚ C for three months and -20˚ C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.

IgG

At least four isoforms of ACVR1 are known to exist. This antibody is predicted to have no cross-reactivity to ACVR1B or ACVR1C.

ACVR1

Activin A receptor, type I

Homo sapiens

Tsuchida K, Sawchenko PN, Nishikawa S, et al. Molecular cloning of a novel type I receptor serine/threonine kinase for the TGF beta superfamily from rat brain. Mol. Cell. Neurosci.1996; 76:467-78.

Ten Dijke P, Yamashita H, Sampath TK, et al. Identification of type I receptors for osteogenic protein-1 and bone morphogenetic protein-4. J. Biol. Chem.1994; 269:16985-8.

Clarke TR, Hoshiya Y, Yi SE, et al. Mullerian inhibiting substance signaling uses a BMP-like pathway mediated by ALK2 and induces Smad6 expression. Mol. Endocrinol.2001; 15:946-59.

Renlund N, O'Neill FH, Zhang L, et al. Activin receptor-like kinase-2 inhibits activin signaling by blocking the binding of activin to its type II receptor. J. Endocrinol.2007; 195:95-103.

ACVR1 Antibody: FOP, ALK2, SKR1, TSRI, ACTRI, ACVR1A, ACVRLK2, Activin receptor type-1, Activin receptor type I, ACTR-I

ELISA, WB

4501895

Liquid